{"id":"seretide-500-accuhaler","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Palpitations"},{"rate":"1-5","effect":"Oral candidiasis"},{"rate":"1-5","effect":"Hoarseness"},{"rate":"1-5","effect":"Muscle cramps"}]},"_chembl":{"chemblId":"CHEMBL3656202","moleculeType":"Small molecule","molecularWeight":"369.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Salmeterol activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and lasting 12 hours. Fluticasone propionate is a corticosteroid that binds glucocorticoid receptors to suppress inflammatory cytokine production and reduce airway edema and mucus secretion. Together, they provide both rapid symptom relief and long-term control of airway obstruction and inflammation.","oneSentence":"Seretide combines a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate) to relax airway smooth muscle and reduce airway inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:32.517Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT02972476","phase":"PHASE4","title":"Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2016-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":158},{"nctId":"NCT00829257","phase":"PHASE4","title":"Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2009-01","conditions":"Asthma","enrollment":15},{"nctId":"NCT01245569","phase":"PHASE3","title":"A Study in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":373},{"nctId":"NCT01570478","phase":"PHASE3","title":"A Study in Patients With Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-07","conditions":"Asthma","enrollment":108},{"nctId":"NCT02195375","phase":"PHASE2, PHASE3","title":"Flutiform® Compared With Seretide® in the Treatment of COPD","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2014-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":923},{"nctId":"NCT01555138","phase":"PHASE4","title":"Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":581},{"nctId":"NCT00974805","phase":"PHASE4","title":"An Investigation of the Mechanism of Action of Seretide in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"University of Southampton","startDate":"2010-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":48},{"nctId":"NCT00655616","phase":"NA","title":"Add-on Salmeterol Versus Montelukast in Arg/Arg-16 Asthmatics","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2007-08","conditions":"Asthma","enrollment":64}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ARRHYTHMIA"},{"count":1,"reaction":"CARDIAC FAILURE CONGESTIVE"},{"count":1,"reaction":"CHEST PAIN"},{"count":1,"reaction":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE"},{"count":1,"reaction":"CYSTITIS"},{"count":1,"reaction":"DIZZINESS"},{"count":1,"reaction":"HEADACHE"},{"count":1,"reaction":"MALAISE"},{"count":1,"reaction":"PAIN IN EXTREMITY"},{"count":1,"reaction":"PNEUMONIA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Seretide 500 Accuhaler","genericName":"Seretide 500 Accuhaler","companyName":"University of Southampton","companyId":"university-of-southampton","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Seretide combines a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate) to relax airway smooth muscle and reduce airway inflammation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}